Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition

Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition

Story continues below

Certain portions of our press release dated March 4, 2019, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed to this Item 2.02. They are as follows:

The 1st through 8th paragraphs relating to results of operations for 2018
The 9th paragraph relating to balance sheet items
The 13th paragraph relating to the conference call to be held on March 4, 2019
The unaudited consolidated statements of income and consolidated balance sheets

Item 7.01 Regulation FD Disclosure

Certain portions of our press release dated March 4, 2019, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed to this Item 7.01 and Regulation FD. They are as follows:

The 10th paragraph relating plans for 2019 product launches
The 11th paragraph relating to 2019 guidance
The 15th paragraph relating to forward looking statements
The balance of such press release not otherwise incorporated by reference in Items 2.02 or 8.01

Item 8.01 Other Events

The 12th paragraph of our press release dated March 4, 2019 relating to our cash dividend is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

99.1 Our press release dated March 4, 2019.

INTER PARFUMS INC Exhibit
EX-99.1 2 s116489_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1     INTER PARFUMS,…
To view the full exhibit click here

About Inc. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

An ad to help with our costs